S
46.78
-0.75 (-1.58%)
| Penutupan Terdahulu | 47.53 |
| Buka | 47.37 |
| Jumlah Dagangan | 2,906,309 |
| Purata Dagangan (3B) | 4,004,600 |
| Modal Pasaran | 112,077,873,152 |
| Harga / Pendapatan (P/E TTM) | 20.16 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.29 |
| Harga / Jualan (P/S) | 2.09 |
| Harga / Buku (P/B) | 1.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 23 Apr 2026 |
| Hasil Dividen (DY TTM) | 4.73% |
| Margin Keuntungan | 13.95% |
| Margin Operasi (TTM) | 20.78% |
| EPS Cair (TTM) | 2.94 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.60% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 65.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 23.01% |
| Nisbah Semasa (MRQ) | 1.46 |
| Aliran Tunai Operasi (OCF TTM) | 9.08 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.94 B |
| Pulangan Atas Aset (ROA TTM) | 4.28% |
| Pulangan Atas Ekuiti (ROE TTM) | 7.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - General (US) | Menaik | Bercampur |
| Drug Manufacturers - General (Global) | Menaik | Bercampur | |
| Stok | Sanofi | Bercampur | Menurun |
AISkor Stockmoo
-0.3
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.5 |
| Purata | -0.25 |
|
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - General |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Institusi | 10.49% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mondrian Investment Partners Ltd | 31 Dec 2025 | 4,495,348 |
| Natixis Advisors, Llc | 31 Dec 2025 | 3,234,911 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion |
| 03 Feb 2026 | Pengumuman | Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion |
| 02 Feb 2026 | Pengumuman | Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease |
| 30 Jan 2026 | Pengumuman | Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease |
| 30 Jan 2026 | Pengumuman | Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease |
| 29 Jan 2026 | Pengumuman | Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026 |
| 29 Jan 2026 | Pengumuman | Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026 |
| Hasil Dividen (DY TTM) | 4.73% |
| Purata Hasil Dividen 5T | 4.99% |
| Nisbah Pembayaran | 75.37% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 04 May 2026 | 14 Apr 2026 | 03 Jun 2026 | 2.422477 Tunai |
| 09 May 2025 | 15 Apr 2025 | 12 Jun 2025 | 2.212154 Tunai |
| 09 May 2024 | 26 Mar 2024 | 06 Jun 2024 | 2.037356 Tunai |
| 09 May 2024 | 26 Mar 2024 | 06 Jun 2024 | 2.0369079 Tunai |
| 30 May 2023 | - | 23 Jun 2023 | 1.9000852 Tunai |
| 26 May 2022 | - | 27 Jun 2022 | 0.2971788 Tunai |
| 04 May 2022 | 20 Apr 2022 | 31 May 2022 | 1.7967514 Tunai |
| 03 May 2021 | 23 Mar 2021 | 26 May 2021 | 1.906064 Tunai |
| 30 Apr 2020 | 05 Mar 2020 | 26 May 2020 | 1.6993994 Tunai |
| 07 May 2019 | - | 31 May 2019 | 1.722322 Tunai |
| 09 May 2018 | 07 Feb 2018 | 04 Jun 2018 | 1.860874 Tunai |
| 11 May 2017 | 16 Feb 2017 | 07 Jun 2017 | 1.577088 Tunai |
| 05 May 2016 | 19 Feb 2016 | 01 Jun 2016 | 1.630252 Tunai |
| 06 May 2015 | 25 Feb 2015 | 02 Jun 2015 | 1.618087 Tunai |
| 17 May 2010 | 12 Feb 2010 | 14 Jun 2010 | 1.62732 Tunai |
| 04 Jun 2007 | 05 Mar 2007 | 03 Jul 2007 | 1.14537 Tunai |
| 02 Jun 2006 | 06 Mar 2006 | 03 Jul 2006 | 0.912 Tunai |
| 02 Jun 2005 | 01 Mar 2005 | 01 Jul 2005 | 0.7993 Tunai |
| Papar semua | |||
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2026 | 2.42 | 1 | 5.18 |
| 2025 | 2.21 | 1 | 4.57 |
| 2024 | 4.07 | 2 | 8.45 |
| 2023 | 1.90 | 1 | 3.82 |
| 2022 | 2.09 | 2 | 4.32 |
| 2021 | 1.91 | 1 | 3.81 |
| 2020 | 1.70 | 1 | 3.50 |
| 2019 | 1.72 | 1 | 3.43 |
| 2018 | 1.86 | 1 | 4.29 |
| 2017 | 1.58 | 1 | 3.67 |
| 2016 | 1.63 | 1 | 4.03 |
| 2015 | 1.62 | 1 | 3.79 |
| 2010 | 1.63 | 1 | 5.05 |
| 2007 | 1.15 | 1 | 2.52 |
| 2006 | 0.912 | 1 | 1.98 |
| 2005 | 0.799 | 1 | 1.82 |
| Papar semua | |||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |